Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study
| Autor: | Oleg S. Chaban, Celine Gruget, Christian de Bodinat, Antti Ahokas, A. Avedisova, F. Picarel-Blanchot, Marek Jarema, Dan J. Stein, Valérie Olivier, Livia Vavrusova |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male medicine.medical_specialty Generalized anxiety disorder International Cooperation Clinical Neurology Placebo-controlled study Placebo Out patients Double blind 03 medical and health sciences 0302 clinical medicine Double-Blind Method Internal medicine Acetamides Outpatients medicine Humans Hypnotics and Sedatives Agomelatine Pharmacology (medical) Psychiatry Biological Psychiatry Retrospective Studies Psychiatric Status Rating Scales Pharmacology Response rate (survey) Dose-Response Relationship Drug Middle Aged medicine.disease Anxiety Disorders 030227 psychiatry Psychiatry and Mental health Treatment Outcome Neurology Tolerability Female Neurology (clinical) Psychology 030217 neurology & neurosurgery Follow-Up Studies medicine.drug |
| Zdroj: | European Neuropsychopharmacology. 27:526-537 |
| ISSN: | 0924-977X |
| DOI: | 10.1016/j.euroneuro.2017.02.007 |
| Popis: | Agomelatine is efficacious in reducing symptoms and preventing relapse in placebo-controlled trials in generalised anxiety disorder (GAD). Nevertheless, fixed dose studies of agomelatine in GAD have not been undertaken. To determine the minimally effective optimal dose of agomelatine in GAD, the efficacy of two doses of agomelatine (10 and 25mg/day) was investigated in a 12-week, placebo-controlled, double-blind, international study in patients with a primary diagnosis of GAD. The primary outcome measure was the Hamilton Anxiety scale (HAM-A). The study was undertaken in 35 clinical centers in Finland, Russia, Poland, Slovakia and Ukraine from August 2013 to January 2015. 131 out-patients were included in the agomelatine 10mg group, 139 in the agomelatine 25mg group, and 142 in the placebo group. Both doses of agomelatine were associated with significant decreases in the HAM-A at week 12 (difference versus placebo of 7.16±1.00 at 10mg and 11.08±0.98 at 25mg, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect